Literature DB >> 6847761

DNA damage as a basis for 4'-demethylepipodophyllotoxin-9-(4,6-O-ethylidene-beta-D-glucopyranoside) (etoposide) cytotoxicity.

A J Wozniak, W E Ross.   

Abstract

The precise mechanism of action of 4'-demethylepipodophyllotoxin-9-(4,6-O-ethylidene-beta-D-glucopyranoside) (VP-16), an important chemotherapeutic agent, has yet to be determined. VP-16 has been shown to cause single-strand breaks (SSBs) in DNA, but their relationship to cytotoxicity has not been determined. We have investigated the action of VP-16 using mouse leukemia L1210 cells in culture. By using the alkaline elution technique, we reaffirmed the occurrence of SSBs in DNA over the drug concentration range 1 to 60 microM. We were able to demonstrate additional types of DNA damage in the form of DNA double-strand breaks and DNA-protein cross-links within the same dose range. The number of double-strand breaks formed per SSB was consistent over this dose range and greater than that found after exposure of L1210 cells to gamma-irradiation. DNA SSBs and double-strand breaks were also shown to occur in isolated nuclei, indicating that cytoplasmic components are not required for this drug action. Colony formation by L1210 cells in soft agar decreased over a drug concentration range similar to that which produced DNA damage. The correlation between the effective dose range in the colony-forming assay and the DNA scission experiments supports the hypothesis that DNA breakage is responsible for drug cytotoxicity. The demonstration of strand scission in isolated nuclei may provide an experimental model for elucidating the exact mechanism of action of VP-16.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6847761

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  40 in total

1.  Ciprofloxacin-induced inhibition of topoisomerase II in human lymphoblastoid cells.

Authors:  A Bredberg; M Brant; M Jaszyk
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

Review 2.  Etoposide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in combination chemotherapy of cancer.

Authors:  J M Henwood; R N Brogden
Journal:  Drugs       Date:  1990-03       Impact factor: 9.546

3.  ATM-mediated KDM2A phosphorylation is required for the DNA damage repair.

Authors:  L-L Cao; F Wei; Y Du; B Song; D Wang; C Shen; X Lu; Z Cao; Q Yang; Y Gao; L Wang; Y Zhao; H Wang; Y Yang; W-G Zhu
Journal:  Oncogene       Date:  2015-03-30       Impact factor: 9.867

4.  Reduced levels of topoisomerase II alpha and II beta in a multidrug-resistant lung-cancer cell line.

Authors:  C D Evans; S E Mirski; M K Danks; S P Cole
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

Review 5.  Etoposide and teniposide. Bioanalysis, metabolism and clinical pharmacokinetics.

Authors:  J J Holthuis
Journal:  Pharm Weekbl Sci       Date:  1988-06-17

6.  Purification of a new peroxidase catalysing the formation of lignan-type compounds.

Authors:  I Frías; J M Siverio; C González; J M Trujillo; J A Pérez
Journal:  Biochem J       Date:  1991-01-01       Impact factor: 3.857

Review 7.  Pharmacokinetics of anticancer drugs in children.

Authors:  W R Crom; A M Glynn-Barnhart; J H Rodman; M E Teresi; R E Kavanagh; M L Christensen; M V Relling; W E Evans
Journal:  Clin Pharmacokinet       Date:  1987-03       Impact factor: 6.447

8.  Effect of fluosol-DA/carbogen on etoposide/alkylating agent antitumor activity.

Authors:  B A Teicher; S D Bernal; S A Holden; K N Cathcart
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

Review 9.  Hypoxia and drug resistance.

Authors:  B A Teicher
Journal:  Cancer Metastasis Rev       Date:  1994-06       Impact factor: 9.264

10.  Antitumor agents. 126. Novel 4 beta-substituted anilino derivatives of 3',4'-O,O-didemethylpodophyllotoxin as potent inhibitors of human DNA topoisomerase II.

Authors:  Z Q Wang; Y C Shen; H X Chen; J Y Chang; X Guo; Y C Cheng; K H Lee
Journal:  Pharm Res       Date:  1993-03       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.